NCT02330640View on ClinicalTrials.gov

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

PHASE4CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 1, 2016

Conditions
Antiplatelet Therapy of Coronary Artery Bypass
Interventions
DRUG

ticagrelor

After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.

DRUG

clopidogrel

After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.

DRUG

asprin

All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study

Trial Locations (1)

100000

FuWaiHospital, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

NCT02330640 - A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting | Biotech Hunter | Biotech Hunter